GO
Loading...

Sanofi SA

More

  • Will ghoulish investments pay off? Monday, 16 Jun 2014 | 6:57 PM ET
    Elderly women wait for lunch to be served at a day care facility on Gogo Island in Matsuyama, Ehime Prefecture, Japan

    As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.

  • NEW YORK, June 16- Morgan Stanley, an adviser to Valeant Pharmaceuticals International Inc in its $53 billion hostile bid for Allergan Inc, initially tried to get hired by Allergan and in its pitch called the unsolicited bidder a "house of cards", according to Allergan.

  • PARIS, June 14- French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes. Under the terms of a memorandum of understanding, Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.

  • PARIS, June 14- French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes. Under the terms of a memorandum of understanding, Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.

  • Diabetes: The $54 billion battleground Friday, 13 Jun 2014 | 12:17 PM ET
    Daily implements of diabetes care.

    Many of the world's biggest drugmakers will gather starting Friday in San Francisco for the American Diabetes Association's annual meeting. Here's what investors need to know.

  • LONDON, June 13- The world's biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal a deal with AstraZeneca remains intense. Even as talks fell apart last month, some in Pfizer's camp remained optimistic the transaction could be revived- and certain AstraZeneca advisers have not ruled out renewed talks.

  • BUSINESS-NEWS-SCHEDULE AT 0830 GMT / 4.30 AM ET Friday, 13 Jun 2014 | 4:50 AM ET

    LONDON- Bank of England Governor Mark Carney says that British interest rates could rise sooner than financial markets expect in a surprisingly stark warning that monetary policy may start to tighten within months. -MARKETS- UK/ REACTION, moved, by Anirban Nag, 480 words.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • Early movers: LULU, FB, AMZN, TWTR, GS, JNJ & more Thursday, 12 Jun 2014 | 7:51 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Orexigen shares plunge on FDA diet-drug delay Wednesday, 11 Jun 2014 | 7:33 AM ET

    Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.

  • June 11- Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug by three months, sending the company's shares down about 19 percent in premarket trading.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • Obesity game-changer? Why this time it's different Monday, 9 Jun 2014 | 12:45 PM ET

    An FDA decision on Orexigen's obesity drug, Contrave, is expected Wednesday, and analysts say its late arrival on market may help.

  • Sanofi boss Viehbacher moves residence to U.S. Tuesday, 3 Jun 2014 | 11:06 AM ET

    PARIS, June 3- Chris Viehbacher, the German-Canadian chief executive of French drugs firm Sanofi, is moving his personal residence from France to the United States for family reasons, a company spokesman said on Tuesday.

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • Erectile drug moves closer to over the counter Thursday, 29 May 2014 | 8:50 AM ET

    Men with ED may be able to avoid the awkwardness of a doctor's visit by buying Cialis without a prescription, under a new proposal. NYT reports.

  • Early movers: AGN, VRS, GE, GOOG & more Wednesday, 28 May 2014 | 7:37 AM ET

    Some of the names on the move ahead of the open.

  • Sanofi, Lilly pursue Cialis over-the-counter approval Wednesday, 28 May 2014 | 2:10 AM ET

    PARIS, May 28- Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and U.S. drugmakers said in a statement on Wednesday.

  • TIMELINE-Early signs of pushback over U.S. drug prices Wednesday, 28 May 2014 | 1:00 AM ET

    May 28- Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost.

  • British cost body recommends Sanofi MS drug Lemtrada Tuesday, 27 May 2014 | 7:01 PM ET

    LONDON, May 28- Britain's healthcare cost-effectiveness watchdog is recommending Sanofi's new multiple sclerosis drug Lemtrada as a treatment option on the state health service, it said on Wednesday.